CURIS INC
S-1, EX-27.4, 2000-11-29
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CURIS INC, S-1, EX-27.3, 2000-11-29
Next: IMPRESO COM INC, 10-K, 2000-11-29



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ONTOGENY,
INC. AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   6-MOS                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-1999
<PERIOD-START>                             JAN-01-2000             JAN-01-1999
<PERIOD-END>                               JUN-30-2000             JUN-30-1999
<CASH>                                      12,182,615                       0
<SECURITIES>                                20,711,167                       0
<RECEIVABLES>                                        0                       0
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                            33,584,654                       0
<PP&E>                                       8,247,595                       0
<DEPRECIATION>                             (3,417,717)                       0
<TOTAL-ASSETS>                              38,853,696                       0
<CURRENT-LIABILITIES>                        5,646,891                       0
<BONDS>                                      2,835,970                       0
                       62,492,792                       0
                                  8,738,123                       0
<COMMON>                                        39,179                       0
<OTHER-SE>                                (40,899,259)                       0
<TOTAL-LIABILITY-AND-EQUITY>              (32,121,957)                       0
<SALES>                                              0                       0
<TOTAL-REVENUES>                             1,497,269               2,493,841
<CGS>                                       18,587,502               9,294,570
<TOTAL-COSTS>                               18,587,502               9,294,570
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                             302,046                 560,598
<INCOME-PRETAX>                           (16,255,929)             (6,107,433)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                       (16,255,929)             (6,107,433)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                              (16,255,929)             (6,107,433)
<EPS-BASIC>                                     (4.66)                  (2.44)
<EPS-DILUTED>                                        0                       0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission